Table 2. Patient characteristics.
| All patients | With pCR | Without pCR | p | |
|---|---|---|---|---|
| Average age on Dx < 40 years |
51.7 (23–79) 16.2% |
48.2 (24–78) 14.7% |
52.0 (23–79) 16.8% |
0.33 0.61 |
| Average BMI BMI > 30 |
28.2 (18.5–47.6) 31.0% |
27.2 (18.5–44.7) 32.1% |
28.5 (20.0–47.6) 30.5% |
0.30 0.82 |
| Clinical stage (TNM) I II III |
2.0% 39.7% 58.3% |
1.0% 39.6% 59.4% |
2.3% 39.7% 58.0% |
0.71 |
| LN compromised No Yes |
19.2% 80.8% |
20.2% 79.8% |
18.4% 81.6% |
0.2 |
| Average Ki67 | 40% | 40% | 30% | 0.08 |
| Subgroup by receptors HR+/HER2−HR+/HER2+ HR−/HER2+ HR−/HER2− |
40.2% 20.9% 18.2% 20.7% |
16.5% 23.0% 38.5% 22.0% |
48.2% 20.3% 11.3% 20.2% |
0.0001a |
| FHx of cancer FHx of BC First degree FHx of BC Fulfils NCCN guidelines for genetic counselling BRCA mutation |
56.5% 30.3% 12.7% 57.0% 6 patients |
74.1% 35.8% 12.3% 63.3% 1 patient |
50.4% 28.4% 12.8% 54.9% 5 patients |
0.0001a 0.21 0.92 0.12 - |
| NeoCT treatment Regime Anthracyclines only Taxanes only Anthracyclines and taxanes (AC-T) If AC-T Dense dose With platinum If HER-2+ Neo trastuzumab + Neo pertuzumab |
11.8% 3.8% 84.4% 19.0% 3.1% 75.9% 4.3% |
0.9% 4.6% 94.5% 20.4% 1.9% 93.5% 9.7% |
15.6% 80.8% 3.6% 18.5% 3.6% 62.0% 0.0% |
0.0001a 0.67 0.41 0.0001a 0.005a |
| Type of surgery TM Axillar dissection |
56.3% 85.0% |
45.2% 85.6% |
59.9% 84.9% |
0.01a 0.87 |
a
Statistical significance pCR: Pathological complete response, Dx: diagnosis, LN: lymph nodes, BMI: body mass index (weight/height2), HFx: family history, BC: breast cancer